Recent analyses on retatrutide, a dual stimulant for glucagon-like peptide-1 and GIP, demonstrate significant outcomes in addressing weight gain and type 2 diabetes. Initial data from clinical assessments point to notable decreases in body mass and enhanced glucose regulation. Additional examinat